Caroline Benedicte Nitter Engen's picture
Andrea Magugliani

Caroline Benedicte Nitter Engen

Postdoctoral Fellow
  • E-mailcaroline.engen@uib.no
  • Visitor Address
    Parkveien 9
    Ida Bloms hus
    5007 Bergen
  • Postal Address
    Postboks 7805
    5020 Bergen

Caroline Engen is a postdoctoral fellow in the Neuro-SysMed centre's research group Philosophy of Neurodegeneration, led by Jan Reinert Karlsen at SVT.

  • Show author(s) (2023). Responsible clinical trials i the age of personalized medicine.
  • Show author(s) (2023). "Evighetsmennesket" – hvilke etiske utfordringer må vi forberede oss på?
  • Show author(s) (2022). Filled with Desire, Perceive Molecules. 17 pages.
  • Show author(s) (2021). Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. Molecular Oncology. 2285-2299.
  • Show author(s) (2021). Reframing cancer: challenging the discourse on cancer and cancer drugs—a Norwegian perspective: Reframing Cancer. BMC Medical Ethics.
  • Show author(s) (2021). FLT3-ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation. Molecular Oncology. 2300-2317.
  • Show author(s) (2021). Enhanced cognitive behaviour therapy (CBT-E) for severe and extreme anorexia nervosa in an outpatient eating disorder unit at a public hospital: a quality-assessment study. Journal of Eating Disorders. 5 pages.
  • Show author(s) (2020). Exploring the boundaries of precision haemato-oncology – The case of FLT3 length mutated acute myeloid leukaemia.
  • Show author(s) (2019). Titrating complex mass cytometry panels. Cytometry Part A. 1-6.
  • Show author(s) (2017). development of novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia.
  • Show author(s) (2017). Cancer Biomarkers: Ethics, Economics and Society. Megaloceros Press.
  • Show author(s) (2016). Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology. 20-29.
  • Show author(s) (2014). Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions. Journal of Clinical Medicine.
  • Show author(s) (2013). Målrettet behandling av akutt myelogen leukemi - hemmere mot FLT3 og andre kinaser viser vei. Best Practice.

More information in national current research information system (CRIStin)